They are an interesting company, spun out of the PHM-X group. They have been executing very well. There was a study that looked at what happens when people are closely monitored and it was very in favour in terms of what Biomed does. This is home monitoring of the COPD disease so they can push them out of hospitals sooner. They were growing at 20% per year organically. He continues to own it. PHM-X also looks really attractive now.
Market. His open ended cannabis mutual fund is being launched on all popular platforms. He has had huge demand. HMMJ-T: There is a strong seasonality in October to November. Fundamentals are pointing to the sector improving. He has not done any shorting but they are very strict on anything happening over their settlement date. There are huge volumes on exchanges due to cannabis. With some shorts when they settled they were not able to deliver the stock. Buy-ins are artificially inflated.